| Challenges for nanoparticle characterization. | |
| | |
MedLine Citation:
|
PMID: 21116950 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The Food and Drug Administration (FDA) and pharmaceutical industry have used standards to assess material biocompatibility, immunotoxicity, purity, and sterility (as well as many other properties) for several decades. Nanoparticle developers and manufacturers leverage well-established methods as much as possible. However, the unique properties of nanomaterials often interfere with standardized protocols, giving false-positive or false-negative results. This chapter provides details of some of the problems which can arise during the characterization of nanoparticle samples. Additionally, we discuss ways to identify, avoid, and resolve such interference, with emphasis on the use of inhibition and enhancement controls. |
| | |
Authors:
|
Scott E McNeil |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Methods in molecular biology (Clifton, N.J.) Volume: 697 ISSN: 1940-6029 ISO Abbreviation: Methods Mol. Biol. Publication Date: 2011 |
Date Detail:
|
Created Date: 2010-11-30 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9214969 Medline TA: Methods Mol Biol Country: United States |
Other Details:
|
Languages: eng Pagination: 9-15 Citation Subset: IM |
Affiliation:
|
Nanotechnology Characterization Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD, USA. ncl@mail.nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
| Grant Support | |
ID/Acronym/Agency:
|
N01-CO-12400/CO/NCI NIH HHS |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Unique benefits of nanotechnology to drug delivery and diagnostics.
Next Document: Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review.